Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas

American Journal of Clinical Pathology

Volumn 141, Issue 5, 2014, Pages 648-655

  Liu, Haiyan ^a   Shi, Jianhui ^a   Prichard, Jeffrey W ^a   Gong, Yun ^b   Lin, Fan ^a  

^a GEISINGER MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast carcinoma; ER negative; GATA 3; GCDFP 15; Mammaglobin

Indexed keywords

ESTROGEN RECEPTOR GROSS CYSTIC DISEASE FLUID PROTEIN 15; MAMMAGLOBIN; TRANSCRIPTION FACTOR GATA 3; TUMOR MARKER; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR; GATA3 PROTEIN, HUMAN; MAMMAGLOBIN A; TUMOR PROTEIN;

ARTICLE; BREAST METASTASIS; DIAGNOSTIC VALUE; ESTROGEN RECEPTOR NEGATIVE INVASIVE DUCTAL CARCINOMA OF THE BREAST; ESTROGEN RECEPTOR NEGATIVE METASTATIC BREAST CARCINOMA; EVALUATION STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; BREAST CARCINOMA; BREAST TUMOR; ER NEGATIVE; GATA-3; GCDFP-15; GENETICS; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY; SECOND CANCER;

BREAST CARCINOMA; ER NEGATIVE; GATA-3; GCDFP-15; MAMMAGLOBIN;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GATA3 TRANSCRIPTION FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMAGLOBIN A; NEOPLASM PROTEINS; NEOPLASMS, SECOND PRIMARY; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84902577549     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP0Q9UQTEESLHN     Document Type: Article

References (40)

1. Watson MA, Fleming TP. Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res. 1996;56:860-865.
2. Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol. 2007;127:103-113.
3. Chia SY, Thike AA, Cheok PY, et al. Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors. Breast. 2010;19:355-359.
4. Rollins-Raval M, Chivukula M, Tseng GC, et al. An immunohistochemical panel to differentiate metastatic breast carcinoma to skin from primary sweat gland carcinomas with a review of the literature. Arch Pathol Lab Med. 2011;135:975-983.
5. Lewis GH, Subhawong AP, Nassar H, et al. Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin. Am J Clin Pathol. 2011;135:587-591.
6. Gomez-Fernandez C, Daneshbod Y, Nassiri M, et al. Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer. Am J Clin Pathol. 2008;130:879-882.
7. Idirisinghe PK, Thike AA, Cheok PY, et al. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer: pathologic correlations and clinical significance. Am J Clin Pathol. 2010;133:416-429.
8. Broom RJ, Tang PA, Simmons C, et al. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res. 2009;29:1557-1562.
9. Finn RS, Press MF, Dering J, et al. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J Clin Oncol. 2009;27:3908-3915.
10. Monaco SE, Wu Y, Teot LA, et al. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas. Diagn Cytopathol. 2013;41:308-315.
11. St Romain P, Madan R, Tawfik OW, et al. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? a clinicopathologic analysis. Hum Pathol. 2012;43:398-404.
12. Aitken SJ, Thomas JS, Langdon SP, et al. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol. 2010;21:1254-1261.
13. Chang HJ, Han SW, Oh DY et al. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab. Jpn J Clin Oncol. 2011;41:593-599.
14. Theurillat JP, Zürrer-Härdi U, Varga Z, et al. Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterparts. Int J Cancer. 2008;122:1585-1591.
15. Jäger D, Filonenko V, Gout I, et al. NY-BR-1 is a differentiation antigen of the mammary gland. Appl Immunohistochem Mol Morphol. 2007;15:77-83.
16. Varga Z, Theurillat JP, Filonenko V, et al. Preferential nuclear and cytoplasmic NY-BR-1 protein expression in primary breast cancer and lymph node metastases. Clin Cancer Res. 2006;12:2745-2751.
17. Woodard AH, Yu J, Dabbs DJ, et al. NY-BR-1 and PAX8 immunoreactivity in breast, gynecologic tract, and other CK7+ carcinomas: potential use for determining site of origin. Am J Clin Pathol. 2011;13:428-435.
18. Balafoutas D, Hausen AZ, Mayer S, et al. Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications. BMC Cancer. 2013;13:271.
19. Burch JB. Regulation of GATA gene expression during vertebrate development. Semin Cell Dev Biol. 2005;16:71-81.
20. Zheng R, Blobel GA. GATA transcription factors and cancer. Genes Cancer. 2010;1:1178-1188.
21. Liu H, Shi J, Wilkerson ML, et al. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol. 2012;138:57-64.
22. Lin F, Zhang PL, Yang XJ, et al. Human kidney injury molecule-1 (hKIM-1): a useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma. Am J Surg Pathol. 2007;31:371-381.
23. Wilkerson ML, Powell E. Tissue microarray. In: Lin F, Prichard J, Liu H, et al., eds. Handbook of Practical Immunohistochemistry: Frequently Asked Questions. New York, NY: Springer; 2011:45-54.
24. Lin F, Shi J, Liu H, et al. Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma with implication of their roles in early tumorigenesis. Am J Surg Pathol. 2008;32:78-91.
25. Lin F, Shi J, Liu H, et al. Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a diagnostic marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus. Am J Clin Pathol. 2008;129:592-605.
26. Lewis GH, Subhawong AP, Nassar H, et al. Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin. Am J Clin Pathol. 2011;135:587-591.
27. Huo L, Zhang J, Gilcrease MZ, et al. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer. Histopathology. 2013;62:267-274.
28. Higgins JP, Kaygusuz G, Wang L, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 2007;31:673-680.
29. Gruver AM, Amin MB, Luthringer DJ, et al. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung. Arch Pathol Lab Med. 2012;136:1339-1346.
30. Chang A, Amin A, Gabrielson E, et al. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Am J Surg Pathol. 2012;36:1472-1476.
31. Gulmann C, Paner GP, Parakh RS, et al. Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract. Hum Pathol. 2013;44:164-172.
32. Schwartz LE, Westra WH, Bishop JA. GATA3 Immunohistochemical expression in salivary gland neoplasms. Mod Pathol. 2013;26 (S2):311-315.
33. Nonaka D, Wang BY, Sun C-CJ. A study of Phox2b and GATA3 expression in tumors of autonomic nervous system derivation. Mod Pathol. 2013;26(S2):136A.
34. Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol. 2010;23:654-661.
35. Albergaria A, Paredes J, Sousa B, et al. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res. 2009;11:R40.
36. Cimino-Mathews A, Subhawong AP, Illei PB, et al. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. Hum Pathol. 2013;44:1341-1349.
37. Hagemann IS, Pfeifer JD, Cao D. Mammaglobin expression in gynecologic adenocarcinomas. Hum Pathol. 2013;44:628-635.
38. Onuma K, Dabbs DJ, Bhargava R. Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium. Int J Gynecol Pathol. 2008;27:418-425.
39. Classen-Linke I, Moss S, Gröting K, et al. Mammaglobin 1: not only a breast-specific and tumour-specific marker, but also a hormone-responsive endometrial protein. Histopathology. 2012;61:955-965.
40. Liu H, Yin H, Wang H, et al. Re-evaluation of immunohistochemical markers in endometrial adenocarcinomas. Mod Pathol. 2012;25(S2):283A.